Anna F. Lau, PhD, D(ABMM) National Institutes of Health

Dr. Lau received her Ph.D. from the University of Sydney, Australia, where her research focused on the development of novel diagnostic platforms for invasive fungal diseases. She completed her CPEP Clinical Microbiology Fellowship training at the NIH and is board-certified through the American Board of Medical Microbiology. In 2013, she joined the Clinical Microbiology Service at the NIH Clinical Center where she co-directed the Bacteriology, Specimen Processing, Parasitology, and Molecular Epidemiology sections. In 2018, Dr. Lau was promoted to Chief of the newly created Sterility Testing Service to support the NIH-wide cGMP aseptic processing and manufacturing of cellular therapy and drug pharmaceuticals for NIH clinical protocols.

Dr. Lau's translational research has focused on the development of rapid diagnostic platforms using molecular-based techniques and mass spectrometry. In her current role, Dr. Lau champions the education of clinical and pharmaceutical colleagues for GMP testing within a hospital environment. Her current research involves advancing testing platforms used in the pharmaceutical setting whilst also meeting FDA requirements for quality and patient safety.